Fairmount Funds Management LLC
- SEC CIK
- 0001802528
- Latest filing
- Aug 14, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 16
- −10 vs. Q3 2022
- Portfolio value
- $630.4M
- +$88.2M (+16.3%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | COM | 2,011,647 | $155.2M | 24.6% | +115,000+6.1% | Added | History |
| NUVLNuvalent, Inc. | COM | 2,788,981 | $83.1M | 13.2% | +709,118+34.1% | Added | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 2,875,526 | $75.1M | 11.9% | +196,544+7.3% | Added | History |
| ONCBeOne Medicines Ltd. | ADR | 239,443 | $52.7M | 8.4% | +153,043+177.1% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,369,623 | $40.0M | 6.3% | 00.0% | Unchanged | History |
| NBIXNeurocrine Biosciences Inc | Stock | 283,000 | $33.8M | 5.4% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 2,758,975 | $31.9M | 5.1% | 00.0% | Unchanged | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 2,543,107 | $29.2M | 4.6% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 1,901,397 | $28.3M | 4.5% | +989,661+108.5% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 73,526 | $27.9M | 4.4% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 2,040,000 | $20.8M | 3.3% | −10,000−0.5% | Reduced | History |
| ANNXAnnexon, Inc. | COM | 3,358,563 | $17.4M | 2.8% | 00.0% | Unchanged | History |
| TRVITrevi Therapeutics, Inc. | COM | 5,696,515 | $11.0M | 1.7% | 00.0% | Unchanged | History |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 7,064,964 | $10.8M | 1.7% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 1,416,998 | $10.8M | 1.7% | 00.0% | Unchanged | History |
| ELVNEnliven Therapeutics, Inc. | COM | 631,333 | $2.58M | 0.4% | +631,333 | New | History |
Sold out since Q3 2022 (11)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| BHVNBiohaven Ltd. | COM | 204,743 | $31.0M | 5.7% | History |
| INSMINSMED Inc | COM PAR $.01 | 1,336,368 | $28.8M | 5.3% | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 469,264 | $24.3M | 4.5% | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,833,950 | $21.9M | 4.0% | History |
| ACADAcadia Pharmaceuticals Inc | COM | 751,804 | $12.3M | 2.3% | History |
| KROSKeros Therapeutics, Inc. | COM | 272,498 | $10.3M | 1.9% | History |
| AMRNAmarin Corp PLC | SPONS ADR NEW | 5,584,837 | $6.09M | 1.1% | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 389,588 | $3.73M | 0.7% | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,231,566 | $3.40M | 0.6% | History |
| TILInstil Bio, Inc. | COM | 673,905 | $3.26M | 0.6% | History |
| ALLKAllakos Inc. | COM | 147,189 | $901.0K | 0.2% | History |